These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 30565388)

  • 1. Defective collagen binding and increased bleeding in a murine model of von Willebrand disease affecting collagen IV binding.
    Slobodianuk TL; Kochelek C; Foeckler J; Kalloway S; Weiler H; Flood VH
    J Thromb Haemost; 2019 Jan; 17(1):63-71. PubMed ID: 30565388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crucial role for the VWF A1 domain in binding to type IV collagen.
    Flood VH; Schlauderaff AC; Haberichter SL; Slobodianuk TL; Jacobi PM; Bellissimo DB; Christopherson PA; Friedman KD; Gill JC; Hoffmann RG; Montgomery RR;
    Blood; 2015 Apr; 125(14):2297-304. PubMed ID: 25662333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and laboratory phenotype variability in type 2M von Willebrand disease.
    Doruelo AL; Haberichter SL; Christopherson PA; Boggio LN; Gupta S; Lentz SR; Shapiro AD; Montgomery RR; Flood VH
    J Thromb Haemost; 2017 Aug; 15(8):1559-1566. PubMed ID: 28544236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The physical spacing between the von Willebrand factor D'D3 and A1 domains regulates platelet adhesion in vitro and in vivo.
    Zhang C; Kelkar A; Nasirikenari M; Lau JTY; Sveinsson M; Sharma UC; Pokharel S; Neelamegham S
    J Thromb Haemost; 2018 Mar; 16(3):571-582. PubMed ID: 29251812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis.
    Casonato A; Sartorello F; Pontara E; Gallinaro L; Bertomoro A; Grazia Cattini M; Daidone V; Szukowska M; Pagnan A
    Thromb Haemost; 2007 Dec; 98(6):1182-7. PubMed ID: 18064311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormal von Willebrand factor secretion, factor VIII stabilization and thrombus dynamics in type 2N von Willebrand disease mice.
    Swystun LL; Georgescu I; Mewburn J; Deforest M; Nesbitt K; Hebert K; Dwyer C; Brown C; Notley C; Lillicrap D
    J Thromb Haemost; 2017 Aug; 15(8):1607-1619. PubMed ID: 28581694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A genetically-engineered von Willebrand disease type 2B mouse model displays defects in hemostasis and inflammation.
    Adam F; Casari C; Prévost N; Kauskot A; Loubière C; Legendre P; Repérant C; Baruch D; Rosa JP; Bryckaert M; de Groot PG; Christophe OD; Lenting PJ; Denis CV
    Sci Rep; 2016 May; 6():26306. PubMed ID: 27212476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease.
    De Meyer SF; Vandeputte N; Pareyn I; Petrus I; Lenting PJ; Chuah MK; VandenDriessche T; Deckmyn H; Vanhoorelbeke K
    Arterioscler Thromb Vasc Biol; 2008 Sep; 28(9):1621-6. PubMed ID: 18556568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional studies on platelet adhesion with recombinant von Willebrand factor type 2B mutants R543Q and R543W under conditions of flow.
    Lankhof H; Damas C; Schiphorst ME; IJsseldijk MJ; Bracke M; Sixma JJ; Vink T; de Groot PG
    Blood; 1997 Apr; 89(8):2766-72. PubMed ID: 9108394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis.
    Denis C; Methia N; Frenette PS; Rayburn H; Ullman-Culleré M; Hynes RO; Wagner DD
    Proc Natl Acad Sci U S A; 1998 Aug; 95(16):9524-9. PubMed ID: 9689113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of a mouse model to elucidate the phenotypic effects of the von Willebrand factor cleavage mutants, Y1605A/M1606A and R1597W.
    Pruss CM; Golder M; Bryant A; Hegadorn C; Haberichter S; Lillicrap D
    J Thromb Haemost; 2012 May; 10(5):940-50. PubMed ID: 22372972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa.
    Marx I; Christophe OD; Lenting PJ; Rupin A; Vallez MO; Verbeuren TJ; Denis CV
    Blood; 2008 Aug; 112(3):603-9. PubMed ID: 18487513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The interaction of von Willebrand factor-A1 domain with collagen: mutation G1324S (type 2M von Willebrand disease) impairs the conformational change in A1 domain induced by collagen.
    Morales LD; Martin C; Cruz MA
    J Thromb Haemost; 2006 Feb; 4(2):417-25. PubMed ID: 16420575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N1421K mutation in the glycoprotein Ib binding domain impairs ristocetin- and botrocetin-mediated binding of von Willebrand factor to platelets.
    Lanke E; Kristoffersson AC; Isaksson C; Holmberg L; Lethagen S
    Eur J Haematol; 2008 Nov; 81(5):384-90. PubMed ID: 18637125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.
    Hillery CA; Mancuso DJ; Evan Sadler J; Ponder JW; Jozwiak MA; Christopherson PA; Cox Gill J; Paul Scott J; Montgomery RR
    Blood; 1998 Mar; 91(5):1572-81. PubMed ID: 9473222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of allele-selective silencing of von Willebrand factor in mice based on a single nucleotide allelic difference in von Willebrand factor.
    Jongejan YK; Linthorst NA; Schrader Echeverri E; Laan SNJ; Dirven RJ; Dahlman JE; van Vlijmen BJM; Denis CV; Eikenboom JCJ
    Thromb Res; 2024 Apr; 236():201-208. PubMed ID: 38461614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a myeloma patient with a life-threatening hemorrhagic diathesis: presence of a lambda dimer protein inhibiting shear-induced platelet aggregation by binding to the A1 domain of von Willebrand factor.
    Shinagawa A; Kojima H; Berndt MC; Kaneko S; Suzukawa K; Hasegawa Y; Shigeta O; Nagasawa T
    Thromb Haemost; 2005 May; 93(5):889-96. PubMed ID: 15886805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discrepant platelet and plasma von Willebrand factor in von Willebrand disease patients with p.Pro2808Leufs*24.
    Bowman ML; Pluthero FG; Tuttle A; Casey L; Li L; Christensen H; Robinson KS; Lillicrap D; Kahr WHA; James P
    J Thromb Haemost; 2017 Jul; 15(7):1403-1411. PubMed ID: 28453889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical von Willebrand factor A1 domain residues influence type VI collagen binding.
    Flood VH; Gill JC; Christopherson PA; Bellissimo DB; Friedman KD; Haberichter SL; Lentz SR; Montgomery RR
    J Thromb Haemost; 2012 Jul; 10(7):1417-24. PubMed ID: 22507569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of human recombinant, plasma-derived and porcine von Willebrand factor in pigs with severe von Willebrand disease.
    Roussi J; Turecek PL; André P; Bonneau M; Pignaud G; Bal dit Sollier C; Schlokat U; Dorner F; Schwarz HP; Drouet L
    Blood Coagul Fibrinolysis; 1998 Jun; 9(4):361-72. PubMed ID: 9690808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.